Outcome of the 37th Annual General Meeting of the Company held on Friday, September 25, 2026.

CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village, Genome Valley Road, Shamirpet Mandal Medchal-Malkajgiri Dist., Hyderabad - 500 101 Telangana, India Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com Date: September 25, 2026 BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 532039 Outcome of the 37th Annual General Meeting (“AGM”) Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the AGM of the Company was held today, i.e., Friday, September 25, 2026, which commenced at 10:30 A.M. IST and ended at 11:30 A.M. IST through Video Conferencing. This communication includes the following: The brief proceedings of the AGM are enclosed herewith as Annexure - A and the transcript of the speech delivered at the AGM by Mr. Azadar Husain Asghar Mehdi Khan (DIN: 01219312), Director, Chairman of the Meeting is enclosed herewith as Annexure - B. For Zenotech Laboratories Limited (Abdul Gafoor Mohammad) Company Secretary & Compliance Officer ICSI Membership No.: A22331 Encl: as above Page 1 of 5 CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village, Genome Valley Road, Shamirpet Mandal Medchal-Malkajgiri Dist., Hyderabad - 500 101 Telangana, India Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com Annexure - A Summary of the Proceedings of the 37th Annual General Meeting held on September 25, 2026 The 37th Annual General Meeting (“AGM/ Meeting”) of the Company was held today i.e., Friday, September 25, 2026 at 10:30 a.m. IST through Video Conferencing in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India, from time to time. 1. The following resolutions were proposed for voting at the 37th AGM and have been approved by the shareholders with requisite majority: Resolution S.No. Details of Resolution Type O rdinary Business: Adoption of audited standalone financial statements of the Company for the Ordinary 1. financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors thereon. Re-appointment of Mr. Jignesh Anantray Goradia (DIN:07229899), who Ordinary 2. retires by rotation and being eligible, had offered himself for re-appointment as Director. S pecial Business: Approval for Material Related Party Transaction(s) with Sun Pharmaceutical Ordinary Industries Limited. 2. Mr. Azadar Husain Asghar Mehdi Khan, Director of the Company, acted as the Chairman of the meeting and, upon confirmation that the requisite quorum is present, conducted its proceedings. 3. All Directors, Key Managerial Personnel, representatives of the Statutory Auditors and Secretarial Auditor participated in the AGM. 4. Remote e-voting facility was made available to the members from September 22, 2026 to September 24, 2026 for the resolutions set out in the Notice of the AGM. Also, an e-voting facility was made available for the shareholders attending the meeting during the AGM and until 15 minutes after the conclusion of the AGM. Page 2 of 5 CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village, Genome Valley Road, Shamirpet Mandal Medchal-Malkajgiri Dist., Hyderabad - 500 101 Telangana, India Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com 5. Mr. Mahadev Tirunagari, Company Secretary in Practice, acted as the Scrutinizer for the e-voting process. 6. The Chairman delivered his speech at the AGM. 7. Registered speaker shareholders were invited to ask questions/ queries, which were suitably addressed by the Chairman. 8. The Chairman requested the Scrutinizer to submit the report to Mr. Abdul Gafoor Mohammad, Company Secretary and Compliance Officer, who is authorized by the Chairman. 9. Mr. Abdul Gafoor Mohammad, Company Secretary & Compliance Officer, proposed a vote of thanks to the Chair and with the Chairman’s permission, declared the Meeting concluded. ***** Page 3 of 5 CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village, Genome Valley Road, Shamirpet Mandal Medchal-Malkajgiri Dist., Hyderabad - 500 101 Telangana, India Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com Annexure - B CHAIRMAN’S SPEECH OF THE 37TH ANNUAL GENERAL MEETING HELD ON SEPTEMBER 25, 2026 Dear Shareholders, Good Morning. On behalf of the Board of Directors, I welcome you all to your Company’s 37th AGM. The global pharmaceutical industry continues to evolve rapidly, driven by innovation, expanding healthcare access, and increasing demand for specialty therapies. Global medicine spending is projected to reach approximately US$2.4 trillion by 2029, supported by broader adoption of innovative medicines, biologics, and treatments for chronic and complex diseases. Emerging markets such as India, Latin America, and parts of Asia remain important growth drivers, while innovation continues to create value across developed markets. I will now share highlights of Zenotech’ s business for the Financial Year 2025-26. During the year under review, the Company recorded revenue of ₹ 3,956.20 Lakhs (Previous year ₹ 3,897.57 Lakhs) from its operations, 1.5% increase over the corresponding previous year, due to 15% increase in volumes mainly in OSD & Ophthalmic sectors which supported in maintaining the estimated revenues. The Company reported loss after tax of ₹ (107.21) Lakhs after adjusting prior period tax expenses ₹ 48.93 Lakhs against previous year reported profit after tax of ₹ 561.29 Lakhs. Based on the projected business plans for the current and forthcoming years, the Company believes that it can restore its positive performance by utilizing its resources to its maximum. Your Company is constantly striving to optimize its operational capacities, restricting costs to remain competitive which would help to improve the operational efficiency. We also continued to work very closely with Sun Pharmaceutical Industries Limited, holding company and promoter of the Company, sharing the best practices and creating new standard operating procedures to ensure that health remain our key focus. Page 4 of 5 CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village, Genome Valley Road, Shamirpet Mandal Medchal-Malkajgiri Dist., Hyderabad - 500 101 Telangana, India Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com Your Company has always maintained high standards of Corporate Governance and we follow a culture that is built on our core values of ethical business conduct. Lastly, I would like to express my sincere thanks to my colleagues on the Board for their wise counsel and guidance and to our promoters for their support and faith in our endeavor. I am thankful to all the Zenotech Team members for their dedicated services and hard work. I sincerely thank all our shareholders who have supported us in our endeavors and also our Bankers, Suppliers and other clients. On behalf of my colleagues on the Board, I assure you that, we will continue to strive in line with your confidence with us. ***** Page 5 of 5